GEC-ESTRO identifies patients who may still benefit from breast brachytherapy boost

GEC-ESTRO supports interstitial brachytherapy boost for selected high-risk breast cancer patients, emphasizing dose escalation with reduced surrounding tissue exposure.

KEY POINTS

  • This narrative literature review by the GEC-ESTRO Breast Cancer Working Group examined 112 publications from 1984–2025, focusing on patient selection and radiotherapy boost techniques after breast-conserving surgery. Its primary objective was to define the continuing role of interstitial brachytherapy (iBT) in the era of hypofractionated whole-breast irradiation, simultaneous integrated boost (SIB), and increasingly individualized local treatment.
  • Randomized trials confirm that a tumor-bed boost reduces local recurrence but increases the risk of fibrosis and cosmetic deterioration without demonstrated overall survival improvement. In the EORTC boost versus no-boost trial, ipsilateral breast tumor recurrence was reported in approximately 9% versus 13% (HR 0.65; p<0.0001), with the greatest absolute benefit among younger women: 11.6 percentage points below age 40, 5.9 points at ages 41–50, and approximately 3 points above age 50.
  • The working group strongly supports a boost for patients younger than 40 years, those younger than 50 years with high-grade disease, extensive intraductal component, or triple-negative phenotype, and those with positive surgical margins when re-excision is not feasible. In contrast, omission may be reasonable for patients older than 50 years with low-grade, hormone receptor-positive disease and negative margins, particularly when otherwise suitable for partial-breast irradiation.
  • Pathological and molecular risk substantially modifies expected boost benefit. In EORTC subgroup analyses, patients younger than 50 with grade 3 tumors experienced reductions in local recurrence from 19.4% to 11.4% or 18.9% to 8.6%, depending on the analysis. For patients younger than 50 with extensive intraductal carcinoma, the reported 20-year recurrence risk decreased from 31% to 15% with boost irradiation.
  • Additional dose escalation must be balanced against late effects. In the randomized Young Boost trial, a 26 Gy boost reduced ten-year locoregional recurrence to 2.8% versus 4.4% with 16 Gy (HR 0.61; p=0.032), but increased moderate or marked fibrosis from 27% to 48%. For HER2-positive disease receiving modern systemic therapy or patients achieving pathological complete response after neoadjuvant treatment, routine boost intensification remains less clearly supported.
  • Interstitial brachytherapy offers rapid dose fall-off and potentially improved sparing of skin, ribs, lung, and uninvolved breast tissue, particularly for deeply situated tumor beds. An EORTC subgroup analysis suggested local recurrence of 3.5% after brachytherapy boost versus 7% after electron boost, but the difference was not statistically significant; importantly, no randomized trial directly compares brachytherapy boost with contemporary external-beam SIB, particularly using modern DIBH techniques.
  • Previously published GEC-ESTRO-ACROP guidance supports HDR brachytherapy boost doses of approximately 10–20 Gy in one to four fractions, depending on the desired biological dose. Preferred options include 2 × 4–6 Gy or 3 × 3–5 Gy, delivered twice daily with at least six hours between fractions, or a single 7–10 Gy fraction. Oncoplastic surgery and displacement of the original tumor bed create additional localization challenges, requiring close surgical–radiotherapy coordination.

CLINICAL TAKEAWAY

Interstitial brachytherapy remains a reasonable tumor-bed boost option for selected high-risk breast cancer patients, particularly when precise dose escalation and sparing of surrounding tissue are important. However, evidence supporting the need for a boost should be distinguished from evidence favoring a particular boost technique, as comparative clinical data against contemporary external-beam SIB remain insufficient and treatment selection should account for late toxicity, anatomy, and available expertise.

SOURCE

Clinical and Translational Radiation Oncology

Browse more research Suggest a correction